
Experts in complex chemistry & peptides to support Life Sciences. Science-led & customer focused: products, services & innovation. Follow us on @BiosynthGroup
- Tweets341
- Following262
- Followers271
- Likes98

ALT Biosynth Carbosynth, a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents, a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD industry. Aalto’s product portfolio includes an extensive range of proteins, antigens, antibodies, disease state human plasma and biospecimens used by the leading diagnostics and vaccine development companies around the world working on emerging diseases and disease variants.



















